Source: Fox News
Summary
A study led by University of California, Berkeley researchers found that the compound TOFA caused significant weight loss in obese mice without reducing food intake or lean mass. Published in Science Advances, the study showed TOFA boosted energy expenditure by blocking lipid production and activating fat-burning genes. When combined with existing obesity drugs like semaglutide, TOFA improved weight loss and metabolic markers. The compound also reduced liver fat and inflammation in mouse models of MASH. However, TOFA has not been tested in humans, and researchers caution that more studies are needed to determine safety and effectiveness.
Our Reading
This guidance has been heard before.
TOFA is another compound that may help with weight loss.
It works differently than current drugs, but the results are still in mice.
Experts warn that human trials are needed before conclusions can be drawn.
The promise of a new treatment feels familiar, but the risks remain unclear.
Author: Evan Null
Source and URL
The article was published by Fox News. The original URL is: https://foxnews.com/health/new-obesity-treatment-may-help-preserve-muscle-weight-loss
Summary of the Article
A team of researchers from the University of California, Berkeley, identified a compound called TOFA that caused significant weight loss in obese mice. The study, published in Science Advances, found that TOFA increased energy expenditure without reducing food intake or lean mass. It also showed promise in reducing liver fat and inflammation in mouse models of MASH. The compound was tested alongside existing weight-loss drugs, with combined treatments showing greater benefits. However, TOFA has not been tested in humans, and more research is needed to determine its safety and effectiveness.
Key Findings
TOFA reduced body weight by 18% in obese mice without affecting food intake or lean mass. It boosted energy expenditure by blocking lipid production and activating fat-burning genes. When combined with drugs like semaglutide, TOFA improved weight loss and metabolic markers. The compound also reduced liver fat and inflammation in mouse models of MASH. However, the study only involved male mice, and no human trials have been conducted yet.
Expert Opinions
Dr. Leslie Pristas, a bariatric surgeon, emphasized the complexity of obesity and warned against assuming any single medication could prevent weight regain. She noted that the body’s weight set point can make it difficult to maintain weight loss after stopping treatment. Pristas also cautioned that early mouse data must be weighed against potential hidden side effects in humans. She stressed that manipulating lipid processing can have complex and unpredictable effects on the body.
Future Research
The study authors acknowledged that TOFA has not been tested in humans, so its safety, appropriate dosage, and long-term effects are unknown. Future studies will need to determine whether TOFA produces similar results in female animals. Researchers also noted that the compound’s potential for human use remains uncertain. The study’s authors disclosed financial ties to a company that may develop TOFA-related therapies, highlighting the need for independent validation of the findings.
